Profile data is unavailable for this security.
About the company
XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.
- Revenue in USD (TTM)0.00
- Net income in USD-35.01m
- Incorporated2005
- Employees94.00
- LocationXBiotech Inc5217 WINNEBAGO LANEAUSTIN 78744United StatesUSA
- Phone+1 (512) 386-2900
- Websitehttp://www.xbiotech.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pyxis Oncology Inc | 16.15m | -59.20m | 202.04m | 51.00 | -- | 1.18 | -- | 12.51 | -1.26 | -1.26 | 0.3269 | 2.88 | 0.0842 | -- | -- | 322,920.00 | -30.87 | -- | -33.12 | -- | 97.06 | -- | -366.67 | -- | -- | -- | 0.0008 | -- | -- | -- | 38.87 | -- | -- | -- |
Candel Therapeutics Inc | 0.00 | -49.99m | 206.31m | 42.00 | -- | -- | -- | -- | -1.70 | -1.70 | 0.00 | -0.321 | 0.00 | -- | -- | 0.00 | -117.35 | -- | -158.61 | -- | -- | -- | -- | -- | -- | -32.70 | 2.36 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
Black Diamond Therapeutics Inc | 0.00 | -80.55m | 206.81m | 54.00 | -- | 1.86 | -- | -- | -1.54 | -1.54 | 0.00 | 1.97 | 0.00 | -- | -- | 0.00 | -59.70 | -40.29 | -67.82 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
Trevi Therapeutics Inc | 0.00 | -38.77m | 209.06m | 25.00 | -- | 3.16 | -- | -- | -0.3879 | -0.3879 | 0.00 | 0.9116 | 0.00 | -- | -- | 0.00 | -44.37 | -47.39 | -47.48 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0014 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
Acrivon Therapeutics Inc | 0.00 | -69.00m | 214.95m | 58.00 | -- | 0.9947 | -- | -- | -2.77 | -2.77 | 0.00 | 6.98 | 0.00 | -- | -- | 0.00 | -35.33 | -- | -37.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
XBiotech Inc | 0.00 | -35.01m | 219.03m | 94.00 | -- | 1.11 | -- | -- | -1.15 | -1.15 | 0.00 | 6.46 | 0.00 | -- | -- | 0.00 | -15.53 | 31.88 | -16.32 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0484 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
Zentalis Pharmaceuticals Inc | 40.56m | -194.65m | 221.15m | 168.00 | -- | 0.578 | -- | 5.45 | -2.75 | -2.75 | 0.5719 | 5.38 | 0.0729 | -- | 15.94 | 241,428.60 | -34.99 | -47.40 | -39.16 | -54.18 | -- | -- | -480.07 | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
Codexis Inc | 60.89m | -76.36m | 221.29m | 174.00 | -- | 3.60 | -- | 3.63 | -1.09 | -1.09 | 0.8723 | 0.8665 | 0.3595 | 6.27 | 3.58 | 349,942.50 | -45.08 | -17.13 | -56.05 | -20.23 | 77.95 | 77.29 | -125.41 | -37.04 | 2.92 | -- | 0.3158 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
Fulcrum Therapeutics Inc | 81.63m | -20.23m | 222.77m | 76.00 | -- | 0.8117 | -- | 2.73 | -0.3507 | -0.3507 | 1.31 | 4.40 | 0.2746 | -- | 29.13 | 1,074,079.00 | -6.81 | -50.55 | -7.14 | -55.91 | -- | -- | -24.79 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
Omeros Corp | 0.00 | -199.92m | 223.10m | 198.00 | -- | -- | -- | -- | -3.32 | -2.35 | 0.00 | -2.15 | 0.00 | -- | -- | 0.00 | -45.24 | -55.51 | -58.74 | -70.10 | -- | -- | -- | -- | -- | -5.74 | 1.42 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
MacroGenics Inc | 41.02m | -136.37m | 225.17m | 339.00 | -- | 3.89 | -- | 5.49 | -2.19 | -2.19 | 0.6583 | 0.9218 | 0.1619 | 6.62 | 6.51 | 120,997.00 | -53.82 | -37.76 | -67.56 | -45.53 | 79.37 | -- | -332.47 | -133.96 | 2.69 | -172.62 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
Corbus Pharmaceuticals Holdings Inc | 0.00 | -34.97m | 228.71m | 19.00 | -- | 1.74 | -- | -- | -5.82 | -5.82 | 0.00 | 10.92 | 0.00 | -- | -- | 0.00 | -35.74 | -86.84 | -45.03 | -130.46 | -- | -- | -- | -769.76 | -- | -29.78 | 0.0794 | -- | -- | -- | -5.33 | -- | -- | -- |
Adaptimmune Therapeutics PLC - ADR | 141.46m | -72.50m | 232.73m | 449.00 | -- | 2.42 | -- | 1.65 | -0.3452 | -0.3452 | 0.5922 | 0.3765 | 0.4256 | -- | 53.33 | 315,053.40 | -21.81 | -41.19 | -28.63 | -48.21 | -- | -- | -51.25 | -714.26 | -- | -- | 0.2058 | -- | 122.05 | 0.2595 | 31.18 | -- | 0.7202 | -- |
Nektar Therapeutics | 93.16m | -177.08m | 235.62m | 137.00 | -- | 2.96 | -- | 2.53 | -0.9007 | -0.9007 | 0.4747 | 0.4329 | 0.2224 | 2.16 | 73.61 | 679,978.10 | -42.28 | -31.02 | -48.54 | -34.63 | 59.22 | 78.04 | -190.09 | -372.21 | 4.90 | -18.76 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
Amarin Corporation plc (ADR) | 264.78m | -33.52m | 236.74m | 275.00 | -- | 0.4292 | -- | 0.8941 | -0.082 | -0.082 | 0.6466 | 1.34 | 0.319 | 0.4395 | 2.15 | 962,832.80 | -4.04 | -4.48 | -5.79 | -6.54 | 61.29 | 75.70 | -12.66 | -8.59 | 2.01 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
Holder | Shares | % Held |
---|---|---|
Millennium Management LLCas of 31 Mar 2024 | 927.37k | 3.05% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 891.02k | 2.93% |
Geode Capital Management LLCas of 30 Jun 2024 | 430.21k | 1.41% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 265.32k | 0.87% |
Credit Suisse AGas of 31 Mar 2024 | 248.27k | 0.82% |
Susquehanna Financial Group LLLPas of 31 Mar 2024 | 169.81k | 0.56% |
Bridgeway Capital Management LLCas of 31 Mar 2024 | 149.32k | 0.49% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 112.99k | 0.37% |
Connor, Clark & Lunn Investment Management Ltd.as of 30 Jun 2024 | 77.72k | 0.26% |
American Century Investment Management, Inc.as of 30 Jun 2024 | 76.46k | 0.25% |